Psoriatic Disease
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.
Infliximab biosimilar uptake rapidly increased only after release of a third option
Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.
‘Pristine’ safety profile sets TYK2i apart from JAK ‘baggage’ in psoriatic disease, lupus
In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.
Primary Care Physician Guide to Psoriatic Disease
Other Biologic Therapy for PsA
Coordinated Management
TNF Inhibitor Therapy for Psoriatic Arthritis
Nonbiologic Therapy for Psoriatic Arthritis
Genetics and Pathogenesis of Psoriatic Arthritis
Lack of training leads to delayed dermatology diagnoses in patients with darker skin tones
Poor representation of darker skin tones in dermatology training materials has led to delayed diagnoses and worse treatment outcomes in Black, Asian and non-white Latin American patients, according to a presenter.